Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate

James R O’Dell,1 Stanley B Cohen,2 J Carter Thorne,3 Joel Kremer4 1Department of Rheumatology, Division of Rheumatology and Immunology, University of Nebraska Medical Center and the Omaha VA, Omaha, NE, USA; 2Department of Internal Medicine, Metroplex Clinical Research Center, University o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	O’Dell JR, Cohen SB, Thorne JC, Kremer J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	biologic claims methotrexate tumor necrosis factor Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/b147cdb749bc44f491f4e1cf469a6d6b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b147cdb749bc44f491f4e1cf469a6d6b
record_format	dspace
spelling	oai:doaj.org-article:b147cdb749bc44f491f4e1cf469a6d6b2021-12-02T06:59:29ZTreatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate1179-156Xhttps://doaj.org/article/b147cdb749bc44f491f4e1cf469a6d6b2018-07-01T00:00:00Zhttps://www.dovepress.com/treatment-of-rheumatoid-arthritis-in-the-usa-premature-use-of-tumor-ne-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156XJames R O’Dell,1 Stanley B Cohen,2 J Carter Thorne,3 Joel Kremer4 1Department of Rheumatology, Division of Rheumatology and Immunology, University of Nebraska Medical Center and the Omaha VA, Omaha, NE, USA; 2Department of Internal Medicine, Metroplex Clinical Research Center, University of Texas Southwestern Medical School, Dallas, TX, USA; 3Division of Rheumatology, University of Toronto, Southlake Regional Health Centre, Toronto, ON, Canada; 4The Center for Rheumatology, Albany Medical College, Albany, NY, USA Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). Results: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). Conclusion: MTX is underused in the treatment of RA in the USA. Keywords: biologic, claims, methotrexate, tumor necrosis factorO’Dell JRCohen SBThorne JCKremer JDove Medical Pressarticlebiologicclaimsmethotrexatetumor necrosis factorDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 10, Pp 97-101 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	biologic claims methotrexate tumor necrosis factor Diseases of the musculoskeletal system RC925-935
spellingShingle	biologic claims methotrexate tumor necrosis factor Diseases of the musculoskeletal system RC925-935 O’Dell JR Cohen SB Thorne JC Kremer J Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
description	James R O’Dell,1 Stanley B Cohen,2 J Carter Thorne,3 Joel Kremer4 1Department of Rheumatology, Division of Rheumatology and Immunology, University of Nebraska Medical Center and the Omaha VA, Omaha, NE, USA; 2Department of Internal Medicine, Metroplex Clinical Research Center, University of Texas Southwestern Medical School, Dallas, TX, USA; 3Division of Rheumatology, University of Toronto, Southlake Regional Health Centre, Toronto, ON, Canada; 4The Center for Rheumatology, Albany Medical College, Albany, NY, USA Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). Results: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). Conclusion: MTX is underused in the treatment of RA in the USA. Keywords: biologic, claims, methotrexate, tumor necrosis factor
format	article
author	O’Dell JR Cohen SB Thorne JC Kremer J
author_facet	O’Dell JR Cohen SB Thorne JC Kremer J
author_sort	O’Dell JR
title	Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
title_short	Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
title_full	Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
title_fullStr	Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
title_full_unstemmed	Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
title_sort	treatment of rheumatoid arthritis in the usa: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/b147cdb749bc44f491f4e1cf469a6d6b
work_keys_str_mv	AT odelljr treatmentofrheumatoidarthritisintheusaprematureuseoftumornecrosisfactorinhibitionandunderutilizationofconcomitantmethotrexate AT cohensb treatmentofrheumatoidarthritisintheusaprematureuseoftumornecrosisfactorinhibitionandunderutilizationofconcomitantmethotrexate AT thornejc treatmentofrheumatoidarthritisintheusaprematureuseoftumornecrosisfactorinhibitionandunderutilizationofconcomitantmethotrexate AT kremerj treatmentofrheumatoidarthritisintheusaprematureuseoftumornecrosisfactorinhibitionandunderutilizationofconcomitantmethotrexate
_version_	1718399655390216192

Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate

Ejemplares similares